Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017703944> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2017703944 endingPage "1553" @default.
- W2017703944 startingPage "1548" @default.
- W2017703944 abstract "Las náuseas y vómitos en el paciente oncológico pueden deberse a diferentes causas, aunque frecuentemente se presentan en relación con los tratamientos de quimio y radioterapia. Sus tipos son: emesis aguda, que se presenta en las primeras 24 horas del tratamiento; retardada, que aparece posteriormente y puede durar varios días y anticipatoria, que sucede antes de administrarse la quimioterapia. Para su tratamiento se utilizan: inhibidores de receptores serotoninérgicos (ondansetrón, granisetrón y palonosetrón) que se utilizan frecuentemente combinados con esteroides (dexametasona); inhibidores del receptor de la neuroquinina (aprepitant y fosaprepitant); otros fármacos (fenotiacinas, haloperidol, metoclopramida, domperidona, benzodiacepinas, antiácidos, anticolinérgicos, cannabinoides…). Los citostáticos se clasifican como altamente emetógenos (se tratan con inhibidores de neuroquinina, antiserotoninérgicos y dexametasona), moderadamente emetógenos (se recomiendan antiserotoninérgicos, dexametasona y ocasionalmente inhibidores de la neuroquinina), de bajo riesgo (tratamiento con dexametasona) y mínimo riesgo (no requieren antieméticos profilácticos). Su eficacia debe reevaluarse en cada ciclo para adaptar el tratamiento a cada necesidad individual. Nausea and vomiting in the cancer patient may have different causes. However, these frequently occur in relation to chemo- and radiotherapy treatments. Their types are: acute emesis, which occurs in the first 24 hours of treatment; delayed, which appears after and may last for several days; and anticipatory, which occurs prior to chemotherapy treatment. The following are used for their treatment: serotonin receptor inhibitors (ondansetron, granisetron and palonosetron), which are frequently used in combination with steroids (dexamethasone); neurokinin receptor inhibitors (aprepitant and fosaprepitant); other drugs (phenothiazines, haloperidol, metoclopramide, domperidone, benzodiazepines, antacids, anticholinergic, cannabinoids, etc.). Cytostatics are classified as highly emetogenic (they are treated with neurokinin inhibitors, antiserotoninergics and dexamethasone), moderately emetogenic (antiserotoninergics, dexamethasone and occasional neurokinin inhibitors are recommended), low risk (treatment with dexamethasone) and minimum risk (they do not require prophylactic antiemetics). Their efficacy should be reevaluated in each cycle to adapt the treatment to each individual need." @default.
- W2017703944 created "2016-06-24" @default.
- W2017703944 creator A5062771484 @default.
- W2017703944 creator A5069201667 @default.
- W2017703944 date "2013-02-01" @default.
- W2017703944 modified "2023-09-27" @default.
- W2017703944 title "Protocolo diagnóstico y terapéutico de las náuseas y vómitos en el paciente oncológico" @default.
- W2017703944 cites W1992358723 @default.
- W2017703944 cites W2065765429 @default.
- W2017703944 cites W2105030925 @default.
- W2017703944 cites W2116682901 @default.
- W2017703944 cites W2123267000 @default.
- W2017703944 cites W2168072459 @default.
- W2017703944 doi "https://doi.org/10.1016/s0304-5412(13)70493-1" @default.
- W2017703944 hasPublicationYear "2013" @default.
- W2017703944 type Work @default.
- W2017703944 sameAs 2017703944 @default.
- W2017703944 citedByCount "0" @default.
- W2017703944 crossrefType "journal-article" @default.
- W2017703944 hasAuthorship W2017703944A5062771484 @default.
- W2017703944 hasAuthorship W2017703944A5069201667 @default.
- W2017703944 hasConcept C126322002 @default.
- W2017703944 hasConcept C2780574406 @default.
- W2017703944 hasConcept C2780852908 @default.
- W2017703944 hasConcept C2780884295 @default.
- W2017703944 hasConcept C29456083 @default.
- W2017703944 hasConcept C71924100 @default.
- W2017703944 hasConceptScore W2017703944C126322002 @default.
- W2017703944 hasConceptScore W2017703944C2780574406 @default.
- W2017703944 hasConceptScore W2017703944C2780852908 @default.
- W2017703944 hasConceptScore W2017703944C2780884295 @default.
- W2017703944 hasConceptScore W2017703944C29456083 @default.
- W2017703944 hasConceptScore W2017703944C71924100 @default.
- W2017703944 hasIssue "25" @default.
- W2017703944 hasLocation W20177039441 @default.
- W2017703944 hasOpenAccess W2017703944 @default.
- W2017703944 hasPrimaryLocation W20177039441 @default.
- W2017703944 hasRelatedWork W1999344589 @default.
- W2017703944 hasRelatedWork W2003594967 @default.
- W2017703944 hasRelatedWork W2058365305 @default.
- W2017703944 hasRelatedWork W2390030148 @default.
- W2017703944 hasRelatedWork W2494584489 @default.
- W2017703944 hasRelatedWork W2748952813 @default.
- W2017703944 hasRelatedWork W2789448498 @default.
- W2017703944 hasRelatedWork W2899084033 @default.
- W2017703944 hasRelatedWork W2910699288 @default.
- W2017703944 hasRelatedWork W4280616544 @default.
- W2017703944 hasVolume "11" @default.
- W2017703944 isParatext "false" @default.
- W2017703944 isRetracted "false" @default.
- W2017703944 magId "2017703944" @default.
- W2017703944 workType "article" @default.